Overview

Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker 2. To evaluate the safety of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker
Phase:
Phase 4
Details
Lead Sponsor:
Otsuka Beijing Research Institute
Treatments:
Cilostazol
Probucol